Chetomin, a SARS-CoV-2 3C-like Protease (3CL(pro)) Inhibitor: In Silico Screening, Enzyme Docking, Molecular Dynamics and Pharmacokinetics Analysis

The emergence of the Coronavirus Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to over 6 million deaths. The 3C-like protease (3CL(pro)) enzyme of the SARS-CoV-2 virus is an attractive druggable target for exploring therapeutic drug c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibrahim, Mahmoud A. A., Abdelrahman, Alaa H. M., Mohamed, Dina E. M., Abdeljawaad, Khlood A. A., Naeem, Mohamed Ahmed, Gabr, Gamal A., Shawky, Ahmed M., Soliman, Mahmoud E. S., Sidhom, Peter A., Paré, Paul W., Hegazy, Mohamed-Elamir F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866112/
https://www.ncbi.nlm.nih.gov/pubmed/36680290
http://dx.doi.org/10.3390/v15010250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866112/
https://www.ncbi.nlm.nih.gov/pubmed/36680290
http://dx.doi.org/10.3390/v15010250

Ejemplares similares